GlassScriptPhysician profile
Amanda M Browne
NPI 1316445877
$18,491.79
in general payments reported to CMS, 2019-2025
38 companies · $7,715 in 2025
The $7,715 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,345 · 2022: $1,452 · 2023: $2,848 · 2024: $5,133 · 2025: $7,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $3,341 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $683 · Consulting Fee: $600 · Entertainment: $313 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,749.55 |
| Travel and Lodging | $3,341.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $682.50 |
| Consulting Fee | $600.00 |
| Entertainment | $313.01 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,165.08 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept Rf Probe |
| Medtronic, INC. | $3,779.93 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Inceptiv |
| Saluda Medical Americas, INC. | $2,718.37 | 2024-2025 | Evoke |
| Foundation Fusion Solutions, LLC | $2,237.51 | 2024-2025 | |
| Abbvie INC. | $984.95 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $594.26 | 2021-2025 | Ztlido |
| Eisai INC. | $377.80 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $346.64 | 2021-2025 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.25 | 2021-2025 | Relistor |
| Pfizer INC. | $287.78 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $220.12 | 2023-2025 | Horizant, Horizant |
| Curonix LLC | $199.57 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Indivior INC. | $193.57 | 2021-2025 | Sublocade |
| Painteq LLC | $188.40 | 2023-2024 | Painteq |
| Idorsia Pharmaceuticals US INC | $166.42 | 2022-2025 | Quviviq, Quviviq |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $159.81 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $147.74 | 2022 | |
| Amgen INC. | $147.42 | 2021-2022 | |
| Allergan, INC. | $139.20 | 2021-2022 | |
| Almatica Pharma LLC | $137.09 | 2022-2023 | Gralise |
| Nevro Corp. | $115.65 | 2022-2023 | Senza |
| Lilly USA, LLC | $111.68 | 2021-2023 | Reyvow, Emgality |
| Vertex Pharmaceuticals Incorporated | $96.13 | 2024-2025 | |
| Lundbeck LLC | $85.37 | 2024-2025 | Vyepti |
| Globus Medical, INC. | $68.48 | 2025 | Senza |
| Upsher-Smith Laboratories LLC | $67.92 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.40 | 2021-2023 | Belsomra |
| Ibsa Pharma INC. | $66.78 | 2023-2024 | Tirosint, Licart, Licart |
| Spr Therapeutics, INC | $62.22 | 2022-2025 | Sprint Pns System |
| Tonix Medicines, INC. | $48.66 | 2025 | Tonmya |
| Relievant Medsystems, INC. | $47.27 | 2023 | Intracept |
| Fidia Pharma USA INC. | $40.13 | 2022-2024 | Hymovis, Hyalgan, Triluron |
| Arbor Pharmaceuticals, INC. | $39.85 | 2021-2022 | |
| Si-Bone, INC. | $22.91 | 2024 | |
| Abbott Laboratories | $22.55 | 2023 | Proclaim |
| Teva Pharmaceuticals USA, INC. | $20.93 | 2022 | |
| Biodelivery Sciences International, INC. | $14.54 | 2021 | |
| Currax Pharmaceuticals LLC | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Browne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.